Literature DB >> 36258087

Current and Emerging Therapies in Pediatric Atopic Dermatitis.

Hadley Johnson1, JiaDe Yu2.   

Abstract

Atopic dermatitis (AD) is the most common inflammatory skin disease seen in children. It is a heterogeneous disorder, with a variety of associated manifestations and symptoms. Cases may range from mild to severe. As a result, a spectrum of prescription and nonprescription therapies may be utilized when managing this condition. This article provides an extensive overview of these therapies, with equal consideration provided to current, emerging, and alternative options used in the pediatric population.
© 2022. The Author(s).

Entities:  

Keywords:  Allergies; Alternatives; Atopic dermatitis; Biologics; Complementary; JAK inhibitors; Pediatric; Phototherapy; Systemics; Topicals

Year:  2022        PMID: 36258087     DOI: 10.1007/s13555-022-00829-4

Source DB:  PubMed          Journal:  Dermatol Ther (Heidelb)


  35 in total

Review 1.  Phototherapy in the Pediatric Population.

Authors:  Michelle C Juarez; Anna L Grossberg
Journal:  Dermatol Clin       Date:  2019-10-18       Impact factor: 3.478

Review 2.  Comorbidities and the impact of atopic dermatitis.

Authors:  Jonathan I Silverberg
Journal:  Ann Allergy Asthma Immunol       Date:  2019-04-26       Impact factor: 6.347

3.  Association Between Malignancy and Topical Use of Pimecrolimus.

Authors:  David J Margolis; Katrina Abuabara; Ole J Hoffstad; Joy Wan; Denise Raimondo; Warren B Bilker
Journal:  JAMA Dermatol       Date:  2015-06       Impact factor: 10.282

4.  The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy.

Authors:  T H Clayton; S M Clark; D Turner; V Goulden
Journal:  Clin Exp Dermatol       Date:  2007-01       Impact factor: 3.470

Review 5.  Keratinocytes: An Enigmatic Factor in Atopic Dermatitis.

Authors:  Pamelika Das; Pappula Mounika; Manoj Limbraj Yellurkar; Vani Sai Prasanna; Sulogna Sarkar; Ravichandiran Velayutham; Somasundaram Arumugam
Journal:  Cells       Date:  2022-05-19       Impact factor: 7.666

6.  No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis.

Authors:  Amy S Paller; Regina Fölster-Holst; Suephy C Chen; Thomas L Diepgen; Craig Elmets; David J Margolis; Brad H Pollock
Journal:  J Am Acad Dermatol       Date:  2020-04-01       Impact factor: 11.527

Review 7.  The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition.

Authors:  Emma Guttman-Yassky; Jon M Hanifin; Mark Boguniewicz; Andreas Wollenberg; Robert Bissonnette; Vivek Purohit; Iain Kilty; Anna M Tallman; Michael A Zielinski
Journal:  Exp Dermatol       Date:  2018-12-12       Impact factor: 3.960

Review 8.  Topical glucocorticoids and the skin--mechanisms of action: an update.

Authors:  A Ahluwalia
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

Review 9.  Molecular Mechanisms of Atopic Dermatitis Pathogenesis.

Authors:  Jowita Sroka-Tomaszewska; Magdalena Trzeciak
Journal:  Int J Mol Sci       Date:  2021-04-16       Impact factor: 5.923

Review 10.  Safety of topical corticosteroids in atopic eczema: an umbrella review.

Authors:  Emma Axon; Joanne R Chalmers; Miriam Santer; Matthew J Ridd; Sandra Lawton; Sinead M Langan; Douglas J C Grindlay; Ingrid Muller; Amanda Roberts; Amina Ahmed; Hywel C Williams; Kim S Thomas
Journal:  BMJ Open       Date:  2021-07-07       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.